What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Health & MedicineOne-Off11MonManifold MarketsKein KYCVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle Community-Prognose60-69% 25.6%Führend unter 7 Optionen
Prognostiker
14
Fragetyp
multiple choice
Methodik
Play-money forecasting platform
Quellentyp
Prognose
7d-Änderung
-2.3 pts
Marktdaten
Aktualisiert vor 18 Stunden
Veraltet15. März 24, 21:29 UTC2. Sept. 27, 06:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will the VLA15 Lyme Disease vaccine "pass" its phase 3 human trial?
Manifold MarketsWill FDA approve any mRNA vaccine against malaria before 2028?
Manifold MarketsWill BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurFDA approves skin cancer vaccine by which date?
PolymarketRegeln
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.
Offene Märkte
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 18.288,2 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 5178,9 €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 weitere Ergebnisse
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Gesamtvolumen
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Gesamtvolumen
- 916.002,6 €
- 24h-Volumen
- 1515,1 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 weitere Ergebnisse
- Gesamtvolumen
- 863.640,2 €
- 24h-Volumen
- 1039 €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Häufige Fragen
- Wie stehen die aktuellen Quoten für What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months??
- Manifold Markets bewertet 60-69% mit 26% (Stand: 8. September 2026).
- Wann wird What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months? entschieden?
- What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months? soll am 2. September 2027 entschieden werden.
- Wie wird What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months? abgerechnet?
- Manifold Markets rechnet diesen Markt wie folgt ab: The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.